Published in Am J Physiol on September 01, 1998
Sildenafil does not improve nitric oxide-mediated endothelium-dependent vascular responses in smokers. Br J Clin Pharmacol (2004) 0.86
Smoking cessation reverses DNA double-strand breaks in human mononuclear cells. PLoS One (2014) 0.80
Effects of Cardiovascular Risk Factors on Endothelial Progenitor Cell. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2014) 0.77
The impact of tetrahydrobiopterin administration on endothelial function before and after smoking cessation in chronic smokers. Hypertens Res (2015) 0.77
Effects of recombinant human thyrotropin administration on 24-hour arterial pressure in female undergoing evaluation for differentiated thyroid cancer. Int J Endocrinol (2014) 0.75
Assessment of endothelial dysfunction in health and disease; using various parameters. Indian J Clin Biochem (2011) 0.75
Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother (1982) 3.90
Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A (2000) 3.48
Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation (1998) 3.25
Fructose-induced insulin resistance and hypertension in rats. Hypertension (1987) 2.43
Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation (1998) 2.35
Implementing clinical practice guidelines while taking account of changing evidence: ATHENA DSS, an easily modifiable decision-support system for managing hypertension in primary care. Proc AMIA Symp (2000) 2.12
Patient compliance and drug failure in protease inhibitor monotherapy. JAMA (1996) 2.06
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci (2001) 1.72
Protein binding and kinetics of drugs in liver diseases. Clin Pharmacokinet (1977) 1.57
Venodilation in Raynaud's disease. Lancet (1993) 1.54
Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest (1992) 1.49
Atenolol determination by high-performance liquid chromatography and fluorescence detection. J Chromatogr (1979) 1.47
Alpha-adrenergic receptor subtypes: quantitative assessment by ligand binding. Life Sci (1979) 1.42
Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. AIDS (1998) 1.42
Repeatability of transcranial Doppler measurements of arterial blood flow velocities in healthy subjects. Clin Sci (Lond) (1993) 1.40
Increased urinary transforming growth factor-beta(1) excretion in children with posterior urethral valves. Urology (2000) 1.40
Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit (1998) 1.36
Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.32
Pharmacokinetics of rifabutin. Antimicrob Agents Chemother (1989) 1.30
Decline in beta adrenergic receptor-mediated vascular relaxation with aging in man. J Pharmacol Exp Ther (1986) 1.28
Defective bromosulfophthalein clearance in patients with constitutional hepatic dysfunction (Gilbert's syndrome). Gastroenterology (1972) 1.28
alpha-Linolenic acid dietary deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex. J Neurochem (1996) 1.26
Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens (1989) 1.24
Alpha-adrenergic receptor subtypes. N Engl J Med (1980) 1.23
Agonist versus antagonist binding to alpha-adrenergic receptors. Proc Natl Acad Sci U S A (1980) 1.22
A role for insulin in the aetiology and course of hypertension? Lancet (1987) 1.21
Vitamin K1 disposition and therapy of warfarin overdose. Lancet (1978) 1.20
Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids (2001) 1.20
Studies on the clinical pharmacology of prazosin. I: Cardiovascular, catecholamine and endocrine changes following a single dose. Br J Clin Pharmacol (1980) 1.19
A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia. Proc Natl Acad Sci U S A (1993) 1.19
Lidocaine blood concentrations during fiberoptic bronchoscopy. Am Rev Respir Dis (1975) 1.14
High-pressure liquid chromatographic analysis of drugs in biological fluids I. Warfarin. J Pharm Sci (1977) 1.14
Inhibition of lipolysis by adenosine is potentiated with age. J Clin Invest (1984) 1.13
Heterogeneity of radioligand binding to alpha-adrenergic receptors. Analysis of guanine nucleotide regulation of agonist binding in relation to receptor subtypes. J Biol Chem (1980) 1.13
A Markov mixed effect regression model for drug compliance. Stat Med (1998) 1.13
Prolonged hyporesponsiveness of vascular smooth muscle contraction after halothane anesthesia in rabbits. Anesth Analg (1985) 1.13
Chronic dietary alpha-linolenic acid deficiency alters dopaminergic and serotoninergic neurotransmission in rats. J Nutr (1994) 1.12
Clinical pharmacokinetics of rifabutin. Clin Pharmacokinet (1995) 1.12
Treatment of paracoccidioidomycosis with itraconazole in a murine model. J Trop Med Hyg (1985) 1.11
High glucose stimulates proliferation and collagen type I synthesis in renal cortical fibroblasts: mediation by autocrine activation of TGF-beta. J Am Soc Nephrol (1999) 1.11
Offline testing of the ATHENA Hypertension decision support system knowledge base to improve the accuracy of recommendations. AMIA Annu Symp Proc (2006) 1.10
Crigler-Najjar syndrome: an unusual course with development of neurologic damage at age eighteen. Pediatr Res (1974) 1.10
Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Pharm Res (2000) 1.09
Differential regulation of the alpha 2-adrenergic receptor by Na+ and guanine nucleotides. Nature (1980) 1.09
Application of salivary concentration data to pharmacokinetic studies with antipyrine. J Pharm Sci (1977) 1.09
Gentamicin pharmacokinetics in neonates undergoing extracorporal membrane oxygenation. Pediatr Infect Dis J (1990) 1.08
Conjugates of catecholamines. II. In vitro and in vivo pharmacological activity of N-alkyl-functionalized carboxylic acid congeners and amides related to isoproterenol. Mol Pharmacol (1983) 1.08
Do we need full compliance data for population pharmacokinetic analysis? J Pharmacokinet Biopharm (1996) 1.08
Pharmacological characterizations of adrenergic receptors in human adipocytes. J Clin Invest (1981) 1.06
Zidovudine response relationships in early human immunodeficiency virus infection. Clin Pharmacol Ther (1993) 1.05
Motor behaviour deficits and their histopathological and functional correlates in the nigrostriatal system of dopamine transporter knockout mice. Neuroscience (2003) 1.04
Medication compliance as a feature in drug development. Annu Rev Pharmacol Toxicol (1997) 1.03
Alpha-adrenergic receptors in liver membranes: delineation with subtype selective radioligands. Life Sci (1981) 1.03
Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics. Clin Pharmacol Ther (2010) 1.03
Modification of dopamine neurotransmission in the nucleus accumbens of rats deficient in n-3 polyunsaturated fatty acids. J Lipid Res (2000) 1.02
Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol Ther (2001) 1.02
Identifying barriers to hypertension guideline adherence using clinician feedback at the point of care. AMIA Annu Symp Proc (2006) 1.02
Chronic n-3 polyunsaturated fatty acid deficiency alters dopamine vesicle density in the rat frontal cortex. Neurosci Lett (2000) 1.02
Age-related decrease in beta adrenergic receptor-mediated vascular smooth muscle relaxation. J Pharmacol Exp Ther (1986) 1.01
Therapy with antisense TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. Am J Physiol Renal Physiol (2000) 1.01
Cardiomyopathy in a rat model of pheochromocytoma. Morphological and functional alterations. Am J Cardiovasc Pathol (1988) 1.01
Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother (1997) 1.01
Pharmacokinetics of intravenous and oral L-arginine in normal volunteers. Br J Clin Pharmacol (1999) 1.01
Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. J Clin Pharmacol (2000) 1.00
Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis. Gastroenterology (1979) 1.00
Heat shock activates c-Src tyrosine kinases and phosphatidylinositol 3-kinase in NIH3T3 fibroblasts. J Biol Chem (1997) 1.00
Desensitization of beta-adrenergic receptors by pheochromocytoma. Endocrinology (1984) 1.00
Nicotine impairs endothelium-dependent dilatation in human veins in vivo. Clin Pharmacol Ther (2000) 1.00
Measurement of ketoconazole, a new antifungal agent, by high-performance liquid chromatography. J Chromatogr (1982) 0.99
alpha1-Adrenergic receptor stimulation of mitogenesis in human vascular smooth muscle cells: role of tyrosine protein kinases and calcium in activation of mitogen-activated protein kinase. J Pharmacol Exp Ther (1999) 0.99
Absence of age-related changes in venous responsiveness to nitroglycerin in vivo in humans. Clin Pharmacol Ther (1987) 0.98
Patient safety in guideline-based decision support for hypertension management: ATHENA DSS. Proc AMIA Symp (2001) 0.97
Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. Clin Pharmacol Ther (2000) 0.97
Hepatic first-pass metabolism in liver disease. Clin Pharmacokinet (1980) 0.97
Alpha-1 adrenergic receptors in the nonfailing and failing human heart. J Pharmacol Exp Ther (1988) 0.97
n-3 polyunsaturated fatty acid supplementation reverses stress-induced modifications on brain monoamine levels in mice. J Lipid Res (2007) 0.96
Stimulation of TGF-beta type II receptor by high glucose in mouse mesangial cells and in diabetic kidney. Am J Physiol Renal Physiol (2000) 0.96
A new approach to quantitation of the various sources of bilrubin in man. J Lab Clin Med (1976) 0.96
Mitochondrial gene mutations in the tRNA(Leu(UUR)) region and diabetes: prevalence and clinical phenotypes in Japan. Clin Chem (2001) 0.96
Vascular reactivity in obstructive sleep apnea syndrome. Am J Respir Crit Care Med (2000) 0.95
Additive hypoglycemic effects of drugs that modify free-fatty acid metabolism by different mechanisms in rats with streptozocin-induced diabetes. Diabetes (1988) 0.95
Role of alpha 1 adrenoceptors in the turnover of phosphatidylinositol and of alpha 2 adrenoceptors in the regulation of cyclic AMP accumulation in hamster adipocytes. Life Sci (1980) 0.95
Glucocorticoids induce transcription and expression of the alpha 1B adrenergic receptor gene in DTT1 MF-2 smooth muscle cells. J Clin Invest (1991) 0.95
Lowering of plasma glucose in diabetic rats by antilipolytic agents. Am J Physiol (1988) 0.94
Effects of clofibrate and warfarin alone and in combination on the disposition of vitamin K1. J Pharmacol Exp Ther (1979) 0.94
Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand. Bull World Health Organ (2001) 0.94
Hospital information systems and the quality of therapeutics. Methods Inf Med (1990) 0.94
The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab Dispos (2000) 0.93
Hypertension as a disease of carbohydrate and lipoprotein metabolism. Am J Med (1989) 0.93
Chronic n-3 polyunsaturated fatty acid diet-deficiency acts on dopamine metabolism in the rat frontal cortex: a microdialysis study. Neurosci Lett (1998) 0.93
Desensitization of alpha-1 adrenergic receptor-mediated vascular smooth muscle contraction. J Pharmacol Exp Ther (1985) 0.93
Differential blockade of voltage-sensitive calcium channels at the mouse neuromuscular junction by novel omega-conopeptides and omega-agatoxin-IVA. J Pharmacol Exp Ther (1995) 0.93